Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
balcinrenone + itraconazole
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The combination of balcinrenone (AZD9977) and itraconazole refers to a clinical study regimen used to evaluate drug-drug interactions. Balcinrenone is a novel, selective, nonsteroidal mineralocorticoid receptor (MR) modulator developed by AstraZeneca for the treatment of heart failure and chronic kidney disease. It acts as a partial MR antagonist, providing cardio-renal protection with a reduced risk of hyperkalemia compared to traditional MR antagonists like eplerenone. Itraconazole is a triazole antifungal agent and a potent inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme. Because balcinrenone is a substrate for CYP3A4, this combination is primarily investigated in Phase 1 clinical pharmacology trials (such as NCT03909750) to determine the impact of strong CYP3A4 inhibition on the pharmacokinetic profile, safety, and tolerability of balcinrenone.
- Brand names
- Sporanox
- Other names
- AZD9977 + itraconazolebalcinrenone + itraconazole
02
Targets
CYP51A1 (Sterol 14α-demethylase)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on balcinrenone + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on balcinrenone + itraconazole.